Latest Breaking News On - Nicolas poirier - Page 8 : comparemela.com

OSE Immunotherapeutics Announces New US Patent Granted for the Use of Tedopi® in Cancer Patients after Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment

OSE Immunotherapeutics Announces New US Patent Granted for the Use of Tedopi® in Cancer Patients after Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFlorence portejoieNicolas poirierTrademark officeNantes university hospitalVeloxis pharmaceuticals incBoehringer ingelheimUnited states patentNon small cell lung cancerUlcerative colitisVeloxis pharmaceuticalsUniversal registration document

OSE Immunotherapeutics Announces New US Patent Granted for the Use of Tedopi in Cancer Patients after Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment

OSE Immunotherapeutics Announces New US Patent Granted for the Use of Tedopi in Cancer Patients after Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesFlorence portejoieNicolas poirierVeloxis pharmaceuticals incTrademark officeNantes university hospitalBoehringer ingelheimRegulatory newsUnited states patentNon small cell lung cancerUlcerative colitisVeloxis pharmaceuticalsUniversal registration documentExecutive officer

OSE Immunotherapeutics SA: OSE Immunotherapeutics Reports on its 2023 Combined General Shareholder s Meeting

OSE Immunotherapeutics SA: OSE Immunotherapeutics Reports on its 2023 Combined General Shareholder s Meeting
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesFlorence portejoieAnne laure autret cornetNicolas poirierJean patrick demonsangDidier hochDominique costantiniElsy boglioliEric leireAlexandre lebeautMaryvonne hianceNantes university hospitalVeloxis pharmaceuticals incBoehringer ingelheimRegulatory newsCombined general shareholder meeting

OSE Immunotherapeutics Reports on its 2023 Combined General Shareholder s Meeting

OSE Immunotherapeutics Reports on its 2023 Combined General Shareholder s Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMaryvonne hianceElsy boglioliAnne laure autret cornetAlexandre lebeautFlorence portejoieDidier hochDominique costantiniNicolas poirierJean patrick demonsangEric leireNantes university hospitalVeloxis pharmaceuticals incBoehringer ingelheimCombined general shareholder meetingGeneral shareholder

OSE Immunotherapeutics Reports on its 2023 Combined General Shareholder s Meeting Seite 1

22.06.2023 - Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General Shareholders’ Meeting were approved as proposed by OSE Immunotherapeutics’ Board of . Seite 1

United statesNicolas poirierEric leireJean patrick demonsangDominique costantiniMaryvonne hianceAnne laure autret cornetCombined shareholder meetingChief executive officerFinancial officerLaure autret cornetChief financialOse immunotherapeutics